{"drugs":["Atazanavir Sulfate","Reyataz"],"mono":{"0":{"id":"927780-s-0","title":"Generic Names","mono":"Atazanavir Sulfate"},"1":{"id":"927780-s-1","title":"Dosing and Indications","sub":[{"id":"927780-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>HIV infection:<\/b> treatment-naive: atazanavir 300 mg\/ritonavir 100 mg ORALLY once daily with food<\/li><li><b>HIV infection:<\/b> treatment-naive, unable to tolerate ritonavir: 400 mg ORALLY once daily with food<\/li><li><b>HIV infection:<\/b> treatment-naive, concomitant use with efavirenz: atazanavir 400 mg\/ritonavir 100 mg ORALLY once daily with food<\/li><li><b>HIV infection:<\/b> treatment-experienced: atazanavir 300 mg\/ritonavir 100 mg ORALLY once daily with food<\/li><li><b>HIV infection:<\/b> treatment-experienced, concomitant use with both tenofovir and an H2-receptor antagonist: atazanavir 400 mg\/ritonavir 100 mg ORALLY once daily with food<\/li><\/ul>"},{"id":"927780-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>HIV infection:<\/b> powder (3 months or older) 10 kg to less than 15 kg, atazanavir 200 mg (4 packets) with ritonavir oral solution 80 mg ORALLY once daily; 15 kg to less than 25 kg, atazanavir 250 mg (5 packets) with ritonavir oral solution 80 mg ORALLY once daily; mix powder with food or beverage and follow immediately with ritonavir oral solution<\/li><li><b>HIV infection:<\/b> capsules (6 years or older, treatment-naive or treatment-experienced, weight-based dosing): 15 kg to less than 20 kg, atazanavir 150 mg with ritonavir 100 mg ORALLY once daily; 20 kg to less than 40 kg, atazanavir 200 mg with ritonavir 100 mg ORALLY once daily; 40 kg or greater, atazanavir 300 mg with ritonavir 100 mg ORALLY once daily; take with food and do not exceed atazanavir 300 mg\/ritonavir 100 mg<\/li><li><b>HIV infection:<\/b>  capsules (13 years or older, 40 kg or greater; treatment-naive and unable to tolerate ritonavir): 400 mg ORALLY once daily with food<\/li><\/ul>"},{"id":"927780-s-1-6","title":"Dose Adjustments","mono":"<ul><li>hepatic impairment, ritonavir is not recommended in patients with any degree of hepatic impairment; atazanavir monotherapy may be used in treatment-naive patients with mild or moderate hepatic impairment<\/li><li>hepatic impairment and treatment-naive, mild (Child-Pugh Class A) 400 mg ORALLY once daily, moderate (Child-Pugh Class B) 300 mg ORALLY once daily<\/li><li><b>renal impairment:<\/b> (not on hemodialysis), no dose adjustment necessary<\/li><li><b>ESRD receiving hemodialysis:<\/b> treatment-naive patients, atazanavir 300 mg with ritonavir 100 mg ORALLY once daily; treatment-experienced patients on hemodialysis should not receive atazanavir<\/li><li><b>pregnancy:<\/b> must administer with ritonavir; for treatment-experienced pregnant women during the second or third trimester requiring coadministration with H2-receptor antagonist OR tenofovir, atazanavir 400 mg with ritonavir 100 mg ORALLY once daily<\/li><\/ul>"},{"id":"927780-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection<br\/>"}]},"3":{"id":"927780-s-3","title":"Contraindications\/Warnings","sub":[{"id":"927780-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use with alfuzosin, cisapride, ergot derivatives, indinavir, irinotecan, lovastatin, midazolam (oral administration), nevirapine, pimozide, rifampin, sildenafil (for treatment of pulmonary arterial hypertension), simvastatin, St John's wort (hypericum perforatum), or triazolam<\/li><li>concomitant use with agents highly dependent on CYP3A or UGT1A1 for clearance and for which elevated plasma concentrations are associated with serious or life-threatening events<\/li><li>concomitant use with strong CYP3A inducers that may reduce exposure or efficacy of atazanavir<\/li><li>hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions), to atazanavir or other components of the product<\/li><\/ul>"},{"id":"927780-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- cardiac conduction abnormalities have been reported<\/li><li>-- use caution in patients with preexisting conduction system disease; monitoring recommended<\/li><li>Dermatologic:<\/li><li>-- Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption, and drug rash with eosinophilia and systemic symptoms [DRESS] syndrome have been reported; discontinue use if severe rash develops<\/li><li>Endocrine and Metabolic:<\/li><li>-- hyperglycemia, diabetic ketoacidosis, and new onset or exacerbation of diabetes mellitus have been reported with protease inhibitor use; initiation or dose adjustment of insulin or oral hypoglycemic agent may be required<\/li><li>Hematologic:<\/li><li>-- increased risk of bleeding, including spontaneous skin hematomas and hemarthrosis have been reported in patients with hemophilia type A or B; additional factor VII was required in some cases<\/li><li>Hepatic:<\/li><li>-- use caution in patients with mild to moderate hepatic impairment (Child-Pugh class B); use unboosted-atazanavir only; dose adjustments recommended for treatment-naive patients<\/li><li>-- use not recommended in patients with severe hepatic impairment (Child-Pugh class C)<\/li><li>-- use of ritonavir-boosted atazanavir is not recommended in patients with hepatic impairment (any degree)<\/li><li>-- increased risk for further transaminase elevation or hepatic decompensation in patients with underlying hepatitis B or C viral infections or patients with elevated transaminase levels at baseline; monitoring before and during therapy recommended<\/li><li>-- hyperbilirubinemia has been reported and may be reversible upon discontinuation; alternative therapies may be considered<\/li><li>Immunologic:<\/li><li>-- immune reconstitution syndrome has been reported and may require evaluation and treatment<\/li><li>-- autoimmune disorders, including Graves disease, polymyositis, and Guillain-Barre syndrome, have been reported in the setting of immune reconstitution syndrome and may occur several months following initiation of treatment<\/li><li>Renal:<\/li><li>-- nephrolithiasis and\/or cholelithiasis has been reported; some cases required hospitalization or experienced complications; interruption or discontinuation of therapy may be warranted<\/li><li>-- use is not recommended in HIV treatment-experienced patients with end-stage renal disease managed by hemodialysis<\/li><li>Other:<\/li><li>-- cross-resistance among protease inhibitors has been reported<\/li><li>-- use not recommended in children younger than 3 months of age due to an increased risk of kernicterus<\/li><li>-- atazanavir oral powder contains phenylalanine which may be harmful to patients with phenylketonuria; each packet contains 35 mg of phenylalanine<\/li><li>Concomitant use:<\/li><li>-- concomitant use of unboosted atazanavir and drugs with a narrow therapeutic index that are highly dependent on CYP2C8 for metabolism, such as paclitaxel or repaglinide is not recommended<\/li><li>-- concomitant use with efavirenz or proton-pump inhibitors in treatment-experienced patients not recommended<\/li><li>-- concomitant use with salmeterol, avanafil, amiodarone, dronedarone, etravirine (regardless of ritonavir boosting), rifapentine, or rivaroxaban is not recommended<\/li><li>-- concomitant use of ritonavir-boosted atazanavir with other protease inhibitors, boceprevir, or voriconazole is not recommended<\/li><li>-- concomitant use of unboosted atazanavir with bosentan, buprenorphine, carbamazepine, phenobarbital, or phenytoin is not recommended<\/li><li>-- concomitant use with colchicine in patients with renal or hepatic impairment is not recommended<\/li><li>-- concomitant use of ritonavir-boosted atazanavir with fluticasone propionate (inhaled or intranasal) is not recommended unless potential benefit outweighs risk of systemic corticosteroid adverse effects<\/li><li>-- concomitant use with systemic budesonide is not recommended unless potential benefit outweighs risk of systemic corticosteroid adverse effects<\/li><\/ul>"},{"id":"927780-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Atazanavir: B (FDA)<\/li><li>Atazanavir: B2 (AUS)<\/li><\/ul>"},{"id":"927780-s-3-12","title":"Breast Feeding","mono":"Atazanavir: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"927780-s-4","title":"Drug Interactions","sub":[{"id":"927780-s-4-13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (probable)<\/li><li>Colchicine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Ergoloid Mesylates (theoretical)<\/li><li>Ergonovine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (theoretical)<\/li><li>Methysergide (theoretical)<\/li><li>Midazolam (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nevirapine (established)<\/li><li>Pazopanib (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (theoretical)<\/li><li>Romidepsin (probable)<\/li><li>Sildenafil (theoretical)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sparfloxacin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"927780-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amlodipine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Avanafil (theoretical)<\/li><li>Axitinib (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (established)<\/li><li>Bosentan (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Cimetidine (theoretical)<\/li><li>Clarithromycin (established)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexlansoprazole (theoretical)<\/li><li>Diltiazem (established)<\/li><li>Disopyramide (probable)<\/li><li>Docetaxel (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Dulaglutide (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Esomeprazole (theoretical)<\/li><li>Etravirine (established)<\/li><li>Exenatide (theoretical)<\/li><li>Famotidine (established)<\/li><li>Felodipine (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Fluvastatin (theoretical)<\/li><li>Fosamprenavir (established)<\/li><li>Garlic (probable)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glargine, Recombinant (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Human Inhaled (theoretical)<\/li><li>Insulin Human Isophane (NPH) (theoretical)<\/li><li>Insulin Human Regular (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Lacosamide (theoretical)<\/li><li>Lamotrigine (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lidocaine (probable)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Lofepramine (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Macitentan (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Minocycline (established)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nicardipine (theoretical)<\/li><li>Nifedipine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nizatidine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Palbociclib (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Pravastatin (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Rabeprazole (theoretical)<\/li><li>Ranitidine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (probable)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Rosuvastatin (probable)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saquinavir (established)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Tenofovir Disoproxil Fumarate (established)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (established)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"},{"id":"927780-s-4-15","title":"Moderate","mono":"<ul><li>Cobicistat (probable)<\/li><li>Dapsone (probable)<\/li><li>Desogestrel (probable)<\/li><li>Didanosine (established)<\/li><li>Dienogest (probable)<\/li><li>Drospirenone (probable)<\/li><li>Efavirenz (established)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Levonorgestrel (probable)<\/li><li>Lopinavir (established)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Mestranol (probable)<\/li><li>Methadone (probable)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Telaprevir (probable)<\/li><li>Trazodone (probable)<\/li><\/ul>"}]},"5":{"id":"927780-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (pediatric, 7%)<\/li><li><b>Dermatologic:<\/b>Rash (Adult, 3% to 20%; pediatric, 14%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (20%), Diarrhea (adult, 15% to 30%; pediatric, 9%), Nausea (20%), Vomiting (pediatric, 12%)<\/li><li><b>Hematologic:<\/b>Neutropenia (pediatric, 9%)<\/li><li><b>Hepatic:<\/b>Increased bilirubin level (Adult, 35% to 49%; pediatrics, 12% to 58%), Jaundice, Unconjugated hyperbilirubinemia, Asymptomatic<\/li><li><b>Neurologic:<\/b>Headache (adult, 25%; pediatric, 8%)<\/li><li><b>Ophthalmic:<\/b>Scleral icterus<\/li><li><b>Respiratory:<\/b>Cough (pediatric, 21%)<\/li><li><b>Other:<\/b>Fever (pediatric, 18%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrioventricular block, Second-degree, Atrioventricular block, Third-degree, Left bundle branch block, Prolonged PR interval, First-degree AV block (5% to 5.9%), Prolonged QT interval (rare), Torsades de pointes<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus, Lactic acidosis<\/li><li><b>Hematologic:<\/b>Decreased hemoglobin, Grade 3 or 4 (Pediatrics, 3%), Neutropenia, Grade 3 or 4 (Pediatrics, 9% to 12%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (Pediatrics, 5%), Increased liver enzymes, Increased serum lipase level (Pediatrics, 5%), Serum amylase raised (Pediatrics, 19%)<\/li><li><b>Immunologic:<\/b>Drug hypersensitivity syndrome, Immune reconstitution syndrome<\/li><li><b>Renal:<\/b>Urolithiasis<\/li><\/ul>"},"6":{"id":"927780-s-6","title":"Drug Name Info","sub":{"0":{"id":"927780-s-6-17","title":"US Trade Names","mono":"Reyataz<br\/>"},"2":{"id":"927780-s-6-19","title":"Class","mono":"<ul><li>Antiretroviral Agent<\/li><li>Antiviral<\/li><li>Protease Inhibitor<\/li><\/ul>"},"3":{"id":"927780-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"927780-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"927780-s-7","title":"Mechanism Of Action","mono":"Atazanavir is an azapeptide HIV-1 protease inhibitor. It prevents formation of mature virions by selectively inhibiting the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells.<br\/>"},"8":{"id":"927780-s-8","title":"Pharmacokinetics","sub":[{"id":"927780-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 2.5 hours<\/li><li>Bioavailability: rapidly absorbed<\/li><li>Effect of food: enhanced bioavailability<\/li><\/ul>"},{"id":"927780-s-8-24","title":"Distribution","mono":"Protein binding: Albumin, 86%; Alpha-1-acid glycoprotein, 89% <br\/>"},{"id":"927780-s-8-25","title":"Metabolism","mono":"Liver: extensive, primarily by CYP3A-mediated monooxygenation and dioxygenation pathways <br\/>"},{"id":"927780-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 79%; 20% unchanged<\/li><li>Renal: 13%; 7% unchanged<\/li><li>Dialyzable: No (hemodialysis), only 2.1% removed<\/li><\/ul>"},{"id":"927780-s-8-27","title":"Elimination Half Life","mono":"<ul><li>healthy and HIV-infected patients, 7 hr<\/li><li>hepatic impairment, 12 hr<\/li><\/ul>"}]},"9":{"id":"927780-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with food<\/li><li>(oral capsules) do not open; swallow whole<\/li><li>(oral powder) mix with at least 1 tablespoon of food such as applesauce or yogurt or at least 30 mL of beverage such as milk, infant formula, or water; follow with an additional 15 mL of beverage added to dose cup to ensure complete dosage<\/li><li>(oral powder) for infants younger than 6 months; may mix in 10 mL of infant formula and administer into cheek with an oral syringe; using oral syringe draw up residual powder with an additional 10 mL of water and administer to ensure complete dosage; administration using an infant bottle is not recommended<\/li><li>(oral powder) administer within 1 hour of preparation<\/li><li>if receiving concomitant buffered medications, didanosine, or antacids, take 2 hours before or 1 hour after<\/li><li>if receiving concomitant H2-receptor antagonists, administer atazanavir 300 mg\/ritonavir 100 mg simultaneously with or at least 10 hours after the H2-receptor antagonist dose<\/li><li>in treatment-naive patients unable to tolerate ritonavir and receiving concomitant H2-receptor antagonists, administer atazanavir 400 mg (without ritonavir) at least 2 hours before or 10 hours after the dose of H2-receptor antagonist<\/li><li>in treatment-naive patients receiving concomitant proton-pump inhibitors, administer atazanavir 300 mg\/ritonavir 100 mg 12 hours after the proton-pump inhibitor dose<\/li><\/ul>"},"10":{"id":"927780-s-10","title":"Monitoring","mono":"<ul><li>(adults and adolescents) viral load at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>(adults and adolescents) CD4 cell counts at baseline and with modification of ARV treatment, then every 3 to 6 months during at least the first 2 years of treatment and if the CD4 counts are less than 300 cell\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>(adults and adolescents) hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>(pediatrics) viral load at baseline and with modification of ARV treatment, within 2 to 4 weeks, then every 3 to 4 months thereafter<\/li><li>(pediatrics) CD4 count\/percentage: at baseline and with modification of ARV treatment, then every 3 to 4 months; less frequent monitoring for children adherent to treatment who have remained clinically stable and have maintained viral suppression and CD4 counts above the threshold for opportunistic infection for more than 2 to 3 years<\/li><li>(pediatrics) clinical history, physical exam, and evaluation of adherence: at baseline at 1 to 2 weeks and 2 to 4 weeks following initiation or modification of ARV treatment, then every 3 to 4 months thereafter<\/li><li>(adults and adolescents) ALT, AST, and total bilirubin at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>(adults and adolescents) basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>(adults and adolescents) CBC with a differential at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>(adults and adolescents) fasting blood glucose or HbA1c at baseline and with modification of ARV treatment, then every 3 to 6 months in patients with abnormal values or every 12 months in patients with normal values<\/li><li>(adults and adolescents) fasting lipid profile at baseline and with modification of ARV treatment, at 4 to 8 weeks, then every 6 to 12 months,<\/li><li>(adults and adolescents) urinalysis at baseline or modification of ARV treatment, then annually<\/li><li>(adults and adolescents) ECG; in patients with preexisting conduction system disease<\/li><li>(pediatrics) ALT and AST at baseline and with modification of ARV treatment, then every 3 to 4 months, or more frequently in at risk patients<\/li><li>(pediatrics) basic chemistry including creatinine, electrolytes, and glucose at baseline and with modification of ARV treatment, at 2 to 4 weeks after treatment initiation, then every 3 to 4 months thereafter<\/li><li>(pediatrics) CBC with differential at baseline and with modification of ARV treatment, within 2 to 4 weeks, then every 3 to 4 months<\/li><li>(pediatrics) random plasma glucose  at baseline and with modification of ARV treatment, at 3 to 6 months after therapy initiation, and once a year thereafter<\/li><li>(pediatrics 2 years or older) non-fasting lipid panel at baseline and with modification of ARV treatment, then every 6 to 12 months; patients with lipid abnormalities should have a fasting lipid panel every 6 months or more frequently as clinically indicated<\/li><li>(pediatrics) urinalysis at baseline, then every 6 to 12 months<\/li><li>(pediatrics) ECG; in patients with preexisting conduction system disease<\/li><\/ul>"},"11":{"id":"927780-s-11","title":"How Supplied","mono":"<b>Reyataz<\/b><br\/><ul><li>Oral Capsule: 150 MG, 200 MG, 300 MG<\/li><li>Oral Powder: 50 MG\/Packet<\/li><\/ul>"},"12":{"id":"927780-s-12","title":"Toxicology","sub":[{"id":"927780-s-12-31","title":"Clinical Effects","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/>USES: Protease inhibitors are used in the treatment of HIV-1 infection. This class includes: atazanavir, darunavir, fosamprenavir calcium, indinavir sulfate, lopinavir\/ritonavir, nelfinavir mesylate, ritonavir, saquinavir mesylate, and tipranavir. PHARMACOLOGY: Protease inhibitors reversibly bind the HIV-1 protease necessary for protein cleavage and subsequent enzyme (reverse transcriptase, protease, and integrase) activation leading to inhibition of infectivity. TOXICOLOGY: Toxicological effects are generally an extension of adverse effects. EPIDEMIOLOGY: Overdose is uncommon and severe sequelae from acute overdose are rare. However, adverse effects and drug interactions are common. OVERDOSE: There are limited overdose data, despite more than 15 years of availability. In general, overdose effects seem to be well tolerated. The following effects have been reported: INDINAVIR: nausea, vomiting, abdominal pain, hematuria, crystalluria, renal insufficiency, and nephrolithiasis. RITONAVIR: vomiting, headache, and rash. ADVERSE EFFECTS: COMMON: Nausea, vomiting, diarrhea, peripheral neuropathy, and elevated liver enzymes are common. SEVERE: Severe effects include pancreatitis, liver failure, myelosuppression, heart block, and lactic acidosis. Other adverse effects specific to each drug include: ATAZANAVIR: hyperglycemia, hyperbilirubinemia (5%), nephrolithiasis, rash, nausea, vomiting, transaminitis, neutropenia (4%), hepatitis. DARUNAVIR: nausea, vomiting, lipodystrophy, transaminitis, hyperglycemia, rash, Stevens-Johnson syndrome (rare), hepatic failure (rare). FOSAMPRENAVIR: Transaminitis, hepatotoxicity (6%). INDINAVIR: Transaminitis, rash, nephrolithiasis (5%), hepatic steatosis (3%), lipodystrophy, and rarely, vasculitis, lactic acidosis, and rhabdomyolysis. LOPINAVIR\/RITONAVIR: hepatotoxicity, rash, hypercholesterolemia, nausea, vomiting, diarrhea. NELFINAVIR: transaminitis, hepatotoxicity (5%). RITONAVIR: nausea, vomiting, abdominal pain, paresthesias, hypercholesterolemia, hepatotoxicity, and rash, all of which are largely dose-dependent. SAQUINAVIR: nausea, vomiting, diarrhea, and abdominal pain are common. TIPRANAVIR: Transaminitis, hepatotoxicity (10%), rash, nausea, vomiting. DRUG INTERACTIONS: Drug interactions are common with this class of medications; most are mediated by Cytochrome P450 3A4. Drugs that are 3A4 inhibitors will decrease the metabolism of most protease inhibitors and increase toxicity. Administration of most protease inhibitors with drugs that are 3A4 substrates decreases metabolism and increases toxicity of these other drugs. Fosamprenavir, nelfinavir, ritonavir, saquinavir, atazanavir, and darunavir are all P450 3A4 substrates and inhibitors. Tipranavir, lopinavir\/ritonavir, and indinavir are P450 3A4 substrates only.<br\/>"},{"id":"927780-s-12-32","title":"Treatment","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Supportive care remains the mainstay of care. Mild transaminitis can be monitored; discontinuation of therapy is usually not necessary. Therapy should be changed for persistently rising transaminases or evidence of hepatic synthetic dysfunction. Nausea and vomiting should be treated with antiemetics. Peripheral neuropathies are generally reversible with drug withdrawal and can be treated with pain management as needed. Mild elevations in lactic acid do not require discontinuation of therapy unless systemic acidemia ensues. MANAGEMENT OF SEVERE TOXICITY: Supportive care remains the mainstay of care in severe toxicity. Withdrawal of the offending agent is imperative to improvement in severe adverse reactions. Stevens-Johnson Syndrome should be treated with supportive care and consideration of corticosteroid and IV immunoglobulin therapy. Granulocyte colony stimulating factor (GCSF) should be considered for neutropenia complicated by infection felt to be secondary to protease inhibitors. Hepatic failure should prompt consultation with a transplant center.<\/li><li>Decontamination: PREHOSPITAL: No prehospital decontamination is indicated. Prehospital care should focus on assessment of vital signs and general supportive care. HOSPITAL: Activated charcoal may be considered for patients who present early after overdose if they are awake and willing to drink the charcoal. Gastric lavage is not indicated as overdose is not life-threatening.<\/li><li>Antidote: None<\/li><li>Monitoring of patient:  Obtain a basic metabolic panel, and monitor CBC and liver enzymes in symptomatic patients. Right upper quadrant ultrasound should be considered to evaluate for alternative etiologies of transaminitis.<\/li><li>Enhanced elimination procedure: Hemodialysis and whole bowel irrigation have no role in the management of protease inhibitor overdose.<\/li><li>Patient disposition: HOME CRITERIA: Suicidal patients should be referred to a healthcare facility. Asymptomatic patients with inadvertent ingestion of a protease inhibitor can be observed at home. OBSERVATION CRITERIA: Asymptomatic or mildly symptomatic patients should be observed for 4 to 6 hours, primarily monitoring signs of co-ingestant toxicity. ADMISSION CRITERIA: Patients with severe toxicity should be admitted. Patients with hepatic failure or severe acidosis should be admitted to an intensive care setting. CONSULT CRITERIA: Infectious disease should be consulted if a change to anti-retroviral therapy is indicated. Consult a medical toxicologist or poison center for patients with severe toxicity or in whom the diagnosis is unclear.<\/li><\/ul>"},{"id":"927780-s-12-33","title":"Range of Toxicity","mono":"<b>AIDS ANTIVIRAL PROTEASE INHIBITORS<\/b><br\/>TOXICITY: INDINAVIR: 52 out of 79 adults developed moderate toxicity after ingesting 2.8 to 48 g; most recovered rapidly. LOPINAVIR\/RITONAVIR: An adult developed vomiting, abdominal pain and headache after ingesting 54 g lopinavir and 13.5 g ritonavir as combination therapy; he recovered. RITONAVIR: An adult, who ingested 1500 mg\/day for 2 days, developed paresthesias which resolved with dose reduction. SAQUINAVIR: An ingestion of 8 g caused no toxicity, and 7200 mg\/day for 25 weeks was well tolerated. THERAPEUTIC DOSE: Varies by specific agent.<br\/>"}]},"13":{"id":"927780-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of cardiac conduction abnormalities (prolonged PR interval, AV block).<\/li><li>Instruct patient to report symptoms of a severe rash (Stevens-Johnson syndrome, erythema multiforme).<\/li><li>Counsel patient to report symptoms of nephrolithiasis and\/or cholelithiasis.<\/li><li>Side effects may include accumulation or redistribution of body fat, headache, abdominal pain, nausea, vomiting, diarrhea, jaundice, myalgia, insomnia, or fever.<\/li><li>Instruct patient to report symptoms of hyperglycemia. Diabetic patient may experience exacerbation of diabetes.<\/li><li>Warn patient to report symptoms of immune reconstitution syndrome.<\/li><li>Advise patient to take drug with food.<\/li><li>Instruct caregiver on the proper preparation of the oral powder.<\/li><li>Counsel patient with phenylketonuria that oral powder contains phenylalanine.<\/li><\/ul>"}}}